Filing Flows › Sanofi (SNY) › Recalls, complaints & regulation
Sanofi (SNY): recalls, clinical trials and Federal Register
Sanofi (SNY) beyond its filings: 0 recalls in the last 12 months (1 in five years, 0 Class I); 9 Federal Register documents in a year; 169 active clinical trials.
Latest recalls
- 2023-05-24 · FDA drug · Admelog, insulin lispro injection, 100 units/mL (U-100), 3mL multi-dose vial, Rx Only, Sanofi-Aventis U.S. LLC, Bridgewater, NJ 08807 A Sanofi Company. NDC 0024
Sanofi's latest quarter
Sanofi, Q3 2026: revenue $14.4B (+16% year over year), operating margin 30.1%, net earnings $3.0B, operating cash flow $3.9B. The chart follows the revenue to costs, profit and cash.
Questions
Has Sanofi had any recalls?
1 recall on file over five years from the FDA, CPSC and NHTSA; 0 in the last 12 months.
How many clinical trials does Sanofi have?
169 active studies on ClinicalTrials.gov, 56 in phase 3.
Updated Nov 9, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.